MA45684A - Protéine d'apport du cerveau - Google Patents
Protéine d'apport du cerveauInfo
- Publication number
- MA45684A MA45684A MA045684A MA45684A MA45684A MA 45684 A MA45684 A MA 45684A MA 045684 A MA045684 A MA 045684A MA 45684 A MA45684 A MA 45684A MA 45684 A MA45684 A MA 45684A
- Authority
- MA
- Morocco
- Prior art keywords
- supply protein
- brain supply
- brain
- protein
- supply
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651065 | 2016-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45684A true MA45684A (fr) | 2019-05-22 |
Family
ID=59593007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045684A MA45684A (fr) | 2016-07-14 | 2017-07-13 | Protéine d'apport du cerveau |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11498974B2 (fr) |
| EP (1) | EP3484918A1 (fr) |
| JP (2) | JP2019529345A (fr) |
| KR (1) | KR20190039696A (fr) |
| CN (1) | CN109476728A (fr) |
| AU (1) | AU2017297804A1 (fr) |
| BR (1) | BR112019000098A2 (fr) |
| CA (1) | CA3028035A1 (fr) |
| IL (1) | IL263773A (fr) |
| MA (1) | MA45684A (fr) |
| MX (1) | MX2019000529A (fr) |
| PH (1) | PH12018502451A1 (fr) |
| RU (1) | RU2019102746A (fr) |
| SG (2) | SG11201810801QA (fr) |
| WO (1) | WO2018011353A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CA3051839A1 (fr) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Anticorps anti-alpha-synucleine et leurs utilisations |
| CA3118692A1 (fr) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Therapie genique de maladies neurodegeneratives a base de cellules |
| CN121754667A (zh) * | 2020-04-08 | 2026-03-31 | 阿里亚达治疗公司 | 用于血脑屏障递送的组合物和方法 |
| CA3220572A1 (fr) | 2021-06-11 | 2022-12-15 | Bioarctic Ab | Molecule de liaison bispecifique |
| WO2023128702A1 (fr) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations |
| US20250304709A1 (en) * | 2022-05-05 | 2025-10-02 | Eli Lilly And Company | Multispecific binding molecules and methods of use thereof |
| WO2024080843A1 (fr) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et son utilisation |
| EP4631975A1 (fr) * | 2022-12-08 | 2025-10-15 | Adel Inc. | Protéine de fusion comprenant un anticorps anti-tau et un peptide et utilisation associée |
| KR20250162888A (ko) | 2023-03-24 | 2025-11-19 | 바이오악틱 에이비 | 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체 |
| US20250000992A1 (en) * | 2023-06-21 | 2025-01-02 | Eli Lilly And Company | Compounds for the delivery of granulin across the blood brain barrier |
| CN121773136A (zh) * | 2023-07-04 | 2026-03-31 | 北京星奇原生物科技有限公司 | 抗-TfR1抗体及其用途 |
| WO2025262228A1 (fr) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Molécule de liaison bispécifique |
| WO2025262225A1 (fr) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Molécule de liaison stabilisée |
| WO2026068513A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison bispécifique |
| WO2026068532A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison bispécifique |
| WO2026068519A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison sensible au ph |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (fr) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention et traitement de la maladie d'alzheimer |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| MX2010011209A (es) | 2008-04-24 | 2010-11-12 | Squibb Bristol Myers Co | Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer. |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| EP2769711A1 (fr) | 2008-07-10 | 2014-08-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Procédés et compositions favorisant l'administration de macromolécules |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| KR101849738B1 (ko) | 2010-06-17 | 2018-04-17 | 트렐리스 바이오싸이언스 인코포레이티드 | 수동 인플루엔자 면역에 유용한 항체 |
| CA2818173C (fr) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Anticorps anti-recepteur de la barriere hemato-encephalique a faible affinite et leurs utilisations |
| HUE045144T2 (hu) * | 2012-08-29 | 2019-12-30 | Hoffmann La Roche | Véragygát-shuttle |
| AU2014332442B2 (en) * | 2013-08-26 | 2019-12-19 | Biontech Research And Development, Inc. | Nucleic acids encoding human antibodies to Sialyl-Lewis |
| CA2944402A1 (fr) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine |
| WO2016005466A2 (fr) * | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | Anticorps se liant aux protofibrilles ass améliorés |
-
2017
- 2017-07-13 BR BR112019000098-4A patent/BR112019000098A2/pt not_active Application Discontinuation
- 2017-07-13 MA MA045684A patent/MA45684A/fr unknown
- 2017-07-13 RU RU2019102746A patent/RU2019102746A/ru not_active Application Discontinuation
- 2017-07-13 CN CN201780042832.1A patent/CN109476728A/zh active Pending
- 2017-07-13 WO PCT/EP2017/067727 patent/WO2018011353A1/fr not_active Ceased
- 2017-07-13 CA CA3028035A patent/CA3028035A1/fr not_active Abandoned
- 2017-07-13 AU AU2017297804A patent/AU2017297804A1/en not_active Abandoned
- 2017-07-13 JP JP2019501707A patent/JP2019529345A/ja active Pending
- 2017-07-13 SG SG11201810801QA patent/SG11201810801QA/en unknown
- 2017-07-13 SG SG10201912842VA patent/SG10201912842VA/en unknown
- 2017-07-13 KR KR1020197002785A patent/KR20190039696A/ko not_active Ceased
- 2017-07-13 US US16/317,156 patent/US11498974B2/en active Active
- 2017-07-13 EP EP17751619.2A patent/EP3484918A1/fr not_active Withdrawn
- 2017-07-13 MX MX2019000529A patent/MX2019000529A/es unknown
-
2018
- 2018-11-21 PH PH12018502451A patent/PH12018502451A1/en unknown
- 2018-12-17 IL IL263773A patent/IL263773A/en unknown
-
2022
- 2022-06-30 JP JP2022106495A patent/JP7589194B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019529345A (ja) | 2019-10-17 |
| SG10201912842VA (en) | 2020-02-27 |
| MX2019000529A (es) | 2020-01-15 |
| CA3028035A1 (fr) | 2018-01-18 |
| RU2019102746A3 (fr) | 2020-11-30 |
| KR20190039696A (ko) | 2019-04-15 |
| IL263773A (en) | 2019-02-28 |
| AU2017297804A1 (en) | 2019-01-24 |
| BR112019000098A2 (pt) | 2019-04-09 |
| US11498974B2 (en) | 2022-11-15 |
| CN109476728A (zh) | 2019-03-15 |
| JP7589194B2 (ja) | 2024-11-25 |
| JP2022130646A (ja) | 2022-09-06 |
| EP3484918A1 (fr) | 2019-05-22 |
| US20190225699A1 (en) | 2019-07-25 |
| SG11201810801QA (en) | 2019-01-30 |
| PH12018502451A1 (en) | 2019-09-30 |
| WO2018011353A1 (fr) | 2018-01-18 |
| RU2019102746A (ru) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45684A (fr) | Protéine d'apport du cerveau | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| EP3463146A4 (fr) | Ensembles chirurgicaux robotiques | |
| EP3547968A4 (fr) | Prothèse obtenu par génie tissulaire | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| KR20180085041A (ko) | 칫솔 | |
| EP3518708A4 (fr) | Structure d'assise souple | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| EP3437540A4 (fr) | Support d'endoscope | |
| HRP20190412T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| DK3145946T3 (da) | Bakteriebaseret proteintilførsel | |
| MA50174A (fr) | Formules de protéines de fusion vegfr-fc | |
| HUE064240T2 (hu) | Fehérjetisztítás | |
| EP3487471A4 (fr) | Tétine artificielle de protection contre les morsures | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| DK3737402T5 (da) | Modificeret protein | |
| MA43873A (fr) | Dspositif d'injection | |
| EP3525479A4 (fr) | Casque d'écoute | |
| EP3583844A4 (fr) | Système d'aquaculture | |
| EP3512771A4 (fr) | Siège d'aéronef | |
| EP3431808A4 (fr) | Butée d'arrêt | |
| EP3445974A4 (fr) | Réchauffeur d'air | |
| EP3444345A4 (fr) | Dérivé d'arnmicro-143 | |
| ZA201902689B (en) | Therapeutic protein | |
| EP3343013A4 (fr) | Collecteur d'admission |